Oncology Central

The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis


Non-small-cell lung cancer (NSCLC) is the main cause of cancer-related death worldwide [1]. In the last decade, new treatments improved the survival of patients with advanced NSCLC and especially of those with adenocarcinoma [2–5]. For patients with advanced tumors harboring activating mutations in the EGFR, targeted agents called EGFR tyrosine kinase inhibitors (EGFR-TKIs) may provide a median overall survival (OS) of approximately 20 months [6–9]. Despite these improvements, few developments have emerged in the treatment of NSCLC with squamous histology, especially after failure of the first-line chemotherapy [10]. A new class of drugs, called immune checkpoint inhibitors, has emerged as promising therapeutic options for these patients [11].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.